Company Website:
http://www.genzyme.com
CAMBRIDGE, Mass. -- (Business Wire)
Genzyme,
a Sanofi company, announced today that the European Commission (EC) has
granted marketing authorization for Cerdelga® (INN:
eliglustat) capsules, a first line oral therapy for certain adults
living with Gaucher disease type 1. A small number of adult patients who
metabolize Cerdelga more quickly or at an undetermined rate, as detected
by an established genetic laboratory test, will not be eligible for
Cerdelga treatment. Cerdelga was approved by the U.S. Food and Drug
Administration in August 2014, and is under review by other regulatory
authorities around the world. It is expected that Cerdelga will be
available commercially in EU countries beginning in 2015 and over the
next few years.
Cerdelga is a potent, highly specific ceramide analogue inhibitor of
glucosylceramide synthase with broad tissue distribution including to
bone marrow. It reduces the production of glucosylceramide, the
substance that builds up in the cells and tissues of people with Gaucher
disease type 1. Cerdelga is indicated in the European Union for the
long-term treatment of adult patients with Gaucher disease type 1 (GD1),
who are CYP2D6 poor metabolizers (PMs), intermediate metabolizers (IMs)
or extensive metabolizers (EMs).
The majority of adverse reactions of Cerdelga are mild and transient.
The most commonly reported adverse reaction with Cerdelga is diarrhea,
in approximately 6% of the patients. The incidence of diarrhea was the
same or higher with placebo than with Cerdelga in the placebo-controlled
pivotal study. Less than 2% of patients receiving Cerdelga permanently
discontinued treatment due to any adverse reaction.
The EC approval was based on data from the Cerdelga clinical development
program, the largest clinical research program ever conducted in Gaucher
disease type 1, with approximately 400 patients treated in 29 countries.
The development program included two pivotal Phase 3 clinical trials. In
a Phase 3 placebo-controlled trial (ENGAGE, a study in treatment-naïve
patients with Gaucher disease type 1) improvements were seen across the
following endpoints after 9 months on Cerdelga: spleen size, platelet
levels, hemoglobin levels, and liver volume. The second Phase 3 trial
was designed to assess disease stability in patients previously treated
with enzyme replacement therapy (ENCORE). That trial met the
pre-specified criteria for non-inferiority to an enzyme replacement
therapy (imiglucerase), which was a composite endpoint of each of the
following parameters: spleen volume, hemoglobin levels, platelet counts,
and liver volume. Patients in the registration studies continued to
receive Cerdelga in the extension periods, and the majority of patients
are in their 4th or 5th year of treatment. In a
Phase 2 clinical study in treatment-naïve patients, Cerdelga has shown a
positive effect on bone parameters including Bone Marrow Burden (BMB)
and Bone Mineral Density (BMD) which was sustained over a period of at
least 4 years. The majority of Phase 2 patients in the extension period
are now in their 8th year of treatment.
About Gaucher Disease
Gaucher disease is an inherited condition affecting fewer than 10,000
people worldwide. People with Gaucher disease do not have enough of an
enzyme, acid β-glucosidase (glucocerebrosidase) that breaks down a
certain type of fat molecule. As a result, lipid engorged cells (called
Gaucher cells) amass in different parts of the body, primarily the
spleen, liver and bone marrow. Accumulation of Gaucher cells may cause
spleen and liver enlargement, anemia, excessive bleeding and bruising,
bone disease and a number of other signs and symptoms. The most common
form of Gaucher disease, type 1, generally does not affect the brain.
About Cerdelga
Cerdelga (eliglustat), a novel glucosylceramide analog given orally, was
designed to partially inhibit the enzyme glucosylceramide synthase,
which results in reduced production of glucosylceramide.
Glucosylceramide is the substance that builds up in the cells and
tissues of people with Gaucher disease. The concept was initially
developed by the late Norman Radin, PhD, from the University of
Michigan. In pre-clinical studies, the molecule, developed with James A.
Shayman, MD, also from the University of Michigan, showed specificity
for glucosylceramide synthase. Following an extensive pre-clinical and
early clinical research program, Cerdelga was studied in the largest
Phase 3 clinical program ever conducted in Gaucher disease.
Cerdelga is registered as an orphan medicinal product for the treatment
of Gaucher disease in the Community Register of Orphan Medicinal
Products.
EU indication and Usage
Cerdelga is indicated for the long-term treatment of adult patients with
Gaucher disease type 1 (GD1), who are CYP2D6 poor metabolizers (PMs),
intermediate metabolizers (IMs) or extensive metabolizers (EMs).
Important Safety Information about Cerdelga for EU patients
Cerdelga is contraindicated in patients who are CYP2D6 intermediate
metabolizers (IMs) or extensive metabolizers (EMs) taking a strong or
moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A
inhibitor, and in patients who are CYP2D6 poor metabolizers (PMs) taking
a strong CYP3A inhibitor. Under these conditions both major metabolic
pathways for eliglustat metabolism are impaired, with predicted
substantially elevated eliglustat plasma concentrations. Although no
significant QTc increases were seen in a thorough QT study in healthy
volunteers, based on PK/PD modelling, eliglustat plasma concentrations
11-fold the predicted human Cmax are predicted to cause mild increases
in the PR, QRS, and QTc intervals.
Use of Cerdelga in patients with pre-existing cardiac conditions has not
been studied during clinical trials. Because eliglustat is predicted to
cause mild increases in ECG intervals at substantially elevated plasma
concentrations, use of Cerdelga should be avoided in patients with
cardiac disease (congestive heart failure, recent acute myocardial
infarction, bradycardia, heart block, ventricular arrhythmia), long QT
syndrome, and in combination with Class IA (e.g. quinidine) and Class
III (e.g. amiodarone, sotalol) antiarrhythmic medicinal products.
Patients should be regularly monitored for clinical response.
The most common side effects of Cerdelga (>2% of patients) are headache,
nausea, diarrhoea, abdominal pain, flatulence, arthralgia, and fatigue.
The most frequently reported serious adverse reaction in clinical
studies was syncope (0.76%). All events were associated with
predisposing risk factors and appeared to be vasovagal in nature. None
of these events led to discontinuation from the study.
Prescribing information and more information about Cerdelga for EU
patients will be available shortly at: http://ec.europa.eu/health/documents/community-register/html/index_en.htm.
For full prescribing information and more information about Cerdelga for
U.S. patients, please visit: http://www.cerdelga.com/pdf/cerdelga_prescribing_information.pdf.
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative
therapies for patients affected by rare and debilitating diseases for
over 30 years. We accomplish our goals through world-class research and
with the compassion and commitment of our employees. With a focus on
rare diseases and multiple sclerosis, we are dedicated to making a
positive impact on the lives of the patients and families we serve. That
goal guides and inspires us every day. Genzyme’s portfolio of
transformative therapies, which are marketed in countries around the
world, represents groundbreaking and life-saving advances in medicine.
As a Sanofi company, Genzyme benefits from the reach and resources of
one of the world’s largest pharmaceutical companies, with a shared
commitment to improving the lives of patients. Learn more at www.genzyme.com.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms:
diabetes solutions, human vaccines, innovative drugs, consumer
healthcare, emerging markets, animal health and Genzyme. Sanofi is
listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Genzyme® and Cerdelga® are registered
trademarks of Genzyme Corporation. All rights reserved.
Forward Looking Statements
This press release contains forward-looking statements as defined in
the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts.
These statements include projections and estimates and their underlying
assumptions, statements regarding plans, objectives, intentions and
expectations with respect to future financial results, events,
operations, services, product development and potential, and statements
regarding future performance. Forward-looking statements are generally
identified by the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks
and uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. These
risks and uncertainties include among other things, the uncertainties
inherent in research and development, future clinical data and analysis,
including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug,
device or biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential of
such product candidates, the absence of guarantee that the product
candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group’s
ability to benefit from external growth opportunities, trends in
exchange rates and prevailing interest rates, the impact of cost
containment policies and subsequent changes thereto, the average number
of shares outstanding as well as those discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including those
listed under “Risk Factors” and “Cautionary Statement Regarding
Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for
the year ended December 31, 2013. Other than as required by applicable
law, Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.
Contacts:
Genzyme
Lori Gorski, 617-768-9344
Lori.Gorski@genzyme.com
Source: Genzyme
© 2024 Canjex Publishing Ltd. All rights reserved.